Innovative strides in immunology have brought forth transformative methodologies, and advances in vaccine research and development now encompass a new era of precision-driven prophylactics. Leveraging mRNA platforms, viral vector systems, and recombinant technologies, scientists are addressing both emerging and re-emerging infectious diseases with unprecedented speed and efficacy. From tailoring antigen design to enhancing adjuvant formulations, research is increasingly focusing on improving immunogenicity and cross-protection. Regulatory strategies and collaborative frameworks have also evolved, expediting approval pathways without compromising safety. Notably, global initiatives are emphasizing equitable access, ensuring that breakthroughs in vaccine science are translated into real-world impact. The integration of artificial intelligence and big data analytics is further optimizing vaccine candidate screening and predictive immunology. Advances in vaccine research and development reflect not just scientific innovation but also a commitment to global health resilience, marking a pivotal shift from reactive responses to proactive prevention strategies in public health systems worldwide.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology Analysis of MPXV and VACV Peptides Underscores the Need to Consider Both MPXV Clades for Vaccine Development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Awareness and acceptability of rotavirus vaccine among mothers of under-five children in Gusau and Bungudu communities of Zamfara state, northwestern Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil